News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
VIPBitget VIP Weekly Research Insights (7.26)In the past three weeks, SOL's price has rebounded strongly from a low of $120 to a high of $185 on July 21. This represents a robust recovery of over 50%, surpassing the rebound seen in BTC, ETH, and most other high-cap altcoins, becoming a strength eco-project worth focusing on.
Bitget·2024/07/26 08:45
VIPRecommended high-quality projects for major clients (July 10) — Ethereum ecosystem assetsBitget·2024/07/10 06:46
VIPRecommended high-quality projects for major clients (June 25) — Bitget Earn projects Bitget·2024/06/25 05:51
VIPRecommended high-quality projects for major clients (June 12) — On-chain Earn projectsBitget·2024/06/17 08:36
VIPRecommended high-quality projects for major clients — June 5Bitget·2024/06/11 06:20
VIPRecommended high-quality projects for major clients — May 30Bitget·2024/05/30 05:28
VIPRecommended high-quality projects for major clients — April 16Bitget·2024/05/23 15:01
VIPRecommended high-quality projects for major clients (May 22) — Ethereum ecosystemBitget·2024/05/22 08:41
VIPRecommended high-quality projects for major clients (May 16) — Base ecosystemBitget·2024/05/16 10:00
VIPRecommended high-quality projects for major clients (May 8) — Ton EcosystemBitget·2024/05/08 05:44
Flash
23:17
From the new UK fiscal year, crypto ETNs cannot be included in mainstream ISA accounts.Starting from the new fiscal year on April 6, UK investors will not be able to add crypto ETNs to their “Stocks and Shares ISA” tax-free accounts. The UK tax authority, HM Revenue and Customs (HMRC), currently classifies crypto ETNs only as assets eligible for the “Innovative Finance ISA,” and at present, no platforms plan to support such products. Investors who already hold crypto ETNs do not need to sell them, and HMRC stated it will continue to assess whether to adjust its policy.
23:10
Due to the impact of data events, Coupang, Inc.'s growth and profitability trends are expected to remain relatively flat in the coming months.This situation may place certain constraints on the company's overall performance. Although Coupang, Inc. has demonstrated strong growth momentum in the past, recent data events may cause its business expansion and profitability to face short-term pressure. Market observers are closely monitoring related developments to assess their long-term impact.
23:08
Rhythm Pharmaceuticals Inc. (referred to as Rhythm Pharmaceuticals) recently disclosed that some of its shareholders plan to further sell up to 2.4 million shares of common stock.This stock sale plan is led by existing shareholders, aiming to achieve their personal asset allocation goals. The transaction is expected to provide additional liquidity to the market, while potentially having some impact on the existing equity structure. The company emphasizes that this stock sale is a personal financial arrangement by the shareholders and does not involve the issuance of new shares by Rhythm Pharmaceuticals, so it will not have a dilutive effect on the company's total capital.